{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:52:53Z","timestamp":1792554773681,"version":"4.5.0"},"reference-count":62,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"publisher","award":["Program for Scientific Publication"],"award-info":[{"award-number":["Program for Scientific Publication"]}],"id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"publisher"}]},{"award":["Program for Scientific Publication"],"award-info":[{"award-number":["Program for Scientific Publication"]}],"id":[{"id":"https:\/\/ror.org\/02xf66n48","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Breast cancer (BC) is a major global public health problem. Classical therapies have limited success on the treatment of BC; therefore, new therapeutic options are needed. Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that represent a revolutionary class of new drug candidates because they induce the degradation of harmful, undruggable proteins by activating the ubiquitination machinery of cells. Their unique mechanism of action offers several advantages over conventional drugs, but also disadvantages, as most of them are large molecules with unfavorable pharmacokinetic properties, which limits their bioavailability. Vepdegestrant (VeppanuTM) is an orally administered, estrogen receptor (ER) targeting chimera that was approved by the FDA on 1 May 2026, for the treatment of adults with ESR1-mutated advanced or metastatic breast cancer. Thus, vepdegestrant became the first-ever approved PROTAC drug. In this article, we briefly summarize the structure, mechanism of action, and key available pharmacokinetic and pharmacological data of vepdegestrant.<\/jats:p>","DOI":"10.3390\/pharmaceutics18070827","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:56:42Z","timestamp":1783349802000},"page":"827","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["From Concept to Clinic: Vepdegestrant (ARV 471) Becomes the First Approved PROTAC Drug"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2424-4523","authenticated-orcid":false,"given":"Mikl\u00f3s","family":"Bege","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem T\u00e9r 1, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Lovas","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem T\u00e9r 1, H-4032 Debrecen, Hungary"},{"name":"Doctoral School of Pharmaceutical Sciences, University of Debrecen, Egyetem T\u00e9r 1, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-4547","authenticated-orcid":false,"given":"Anik\u00f3","family":"Borb\u00e1s","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of Debrecen, Egyetem T\u00e9r 1, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"20211033","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1021\/acs.jmedchem.3c00136","article-title":"Targeting the estrogen receptor for the treatment of breast cancer: Recent advances and challenges","volume":"66","author":"Rej","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rani, A., Stebbing, J., Giamas, G., and Murphy, J. (2019). Endocrine resistance in hormone receptor positive breast cancer\u2013from mechanism to therapy. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00245"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Haque, M.M., and Desai, K.V. (2019). Pathways to endocrine therapy resistance in breast cancer. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00573"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2165\/00003495-200161060-00013","article-title":"Fulvestrant","volume":"61","author":"Curran","year":"2001","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.bjc.6601630","article-title":"Fulvestrant: Pharmacokinetics and pharmacology","volume":"90","author":"Robertson","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e188051","DOI":"10.1172\/jci.insight.188051","article-title":"Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor\u2013positive breast cancer","volume":"10","author":"Sherman","year":"2025","journal-title":"JCI Insight"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.1039\/D2CS00117A","article-title":"SERDs: A case study in targeted protein degradation","volume":"51","author":"Wang","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e202100270","DOI":"10.1002\/cbic.202100270","article-title":"Recent developments in PROTAC-mediated protein degradation: From bench to clinic","volume":"23","author":"Hu","year":"2022","journal-title":"ChemBioChem"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1016\/j.apsb.2021.07.017","article-title":"Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity","volume":"11","author":"Lu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"118055","DOI":"10.1016\/j.ejmech.2025.118055","article-title":"Global landscape of PROTAC: Perspectives from patents, drug pipelines, clinical trials, and licensing transactions","volume":"299","author":"Cai","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_13","first-page":"2215","article-title":"Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway","volume":"14","author":"Ottis","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","article-title":"Dutch-Belgian HOVON group; German GMMG Group. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance","volume":"121","author":"Broyl","year":"2013","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bjh.12338","article-title":"High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone","volume":"161","author":"Heintel","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eabn2707","DOI":"10.1126\/scisignal.abn2707","article-title":"The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells","volume":"15","author":"Kurimchak","year":"2022","journal-title":"Sci. Signal."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e202501111","DOI":"10.1002\/cmdc.202501111","article-title":"Insights Into Vepdegestrant (ARV-471): The First-in-Class Estrogen Receptor Proteolysis-Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer","volume":"21","author":"Tang","year":"2026","journal-title":"ChemMedChem"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular Properties That Influence the Oral Bioavailability of Drug Candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103387","DOI":"10.1016\/j.drudis.2022.103387","article-title":"Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)","volume":"28","author":"Saraswat","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1021\/acs.molpharmaceut.6c00207","article-title":"The In Vivo Effect of Amorphous Drug Nanoprecipitates on the Intestinal Absorption of the PROTACs ARV-110 (Bavdeglutamide) and ARV-471(Vepdegestrant)","volume":"23","author":"Niessen","year":"2026","journal-title":"Mol. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"114719","DOI":"10.1016\/j.ejpb.2025.114719","article-title":"A comprehensive mechanistic investigation of factors affecting intestinal absorption and bioavailability of two PROTACs in rats","volume":"211","author":"Niessen","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"116348","DOI":"10.1016\/j.jpba.2024.116348","article-title":"Development and validation of LC-MS\/MS methods for the pharmacokinetic assessment of the PROTACs bavdeglutamide (ARV-110) and vepdegestrant (ARV-471)","volume":"249","author":"Niessen","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Choi, H.-I., Choi, J., Kim, J.W., Lee, Y.H., Cho, K.H., and Koo, T.-S. (2024). Stability Evaluation and Pharmacokinetic Profiling of Vepdegestrant in Rodents Using Liquid Chromatography\u2013Tandem Mass Spectrometry. Molecules, 29.","DOI":"10.3390\/molecules29174048"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101175","DOI":"10.1016\/j.jpha.2024.101175","article-title":"Characterization of preclinical radio ADME properties of ARV-471 for predicting human PK using PBPK modeling","volume":"15","author":"He","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1124\/dmd.124.001661","article-title":"Application of electro-activated dissociation fragmentation technique to identifying glucuronidation and oxidative metabolism sites of vepdegestrant by liquid chromatography-high resolution mass spectrometry","volume":"52","author":"He","year":"2024","journal-title":"Drug Metab. Dispos."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/bcp.70482","article-title":"Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults","volume":"92","author":"Wang","year":"2026","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clinthera.2025.12.007","article-title":"The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants","volume":"48","author":"Tran","year":"2026","journal-title":"Clin. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.clinthera.2026.03.005","article-title":"Letter to the Editor Regarding \u201cThe Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants\u201d Recently Published by Tran and Colleagues","volume":"48","author":"Niessen","year":"2026","journal-title":"Clin. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1002\/bcp.70198","article-title":"Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants","volume":"91","author":"Yang","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10147-024-02648-3","article-title":"Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: A phase 1 study","volume":"30","author":"Iwata","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3892\/ol.2024.14278","article-title":"Recommendations for cyclin-dependent kinase 4\/6 inhibitor treatments in the context of co-morbidity and drug interactions (Review)","volume":"27","author":"Teomete","year":"2024","journal-title":"Oncol. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"George, M.A., Qureshi, S., Omene, C., Toppmeyer, D.L., and Ganesan, S. (2021). Clinical and Pharmacologic Differences of CDK4\/6 Inhibitors in Breast Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.693104"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/j.annonc.2023.09.567","article-title":"390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+\/human epidermal growth factor receptor 2 (HER2)-advanced breast cancer: Update of dose escalation results from a phase I\/II trial","volume":"34","author":"Hamilton","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"PO3-05-08","DOI":"10.1158\/1538-7445.SABCS23-PO3-05-08","article-title":"Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER\u2013positive\/human epidermal growth factor receptor 2 (HER2)\u2013negative advanced breast cancer","volume":"84","author":"Hurvitz","year":"2024","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"GS3-03","DOI":"10.1158\/1538-7445.SABCS22-GS3-03","article-title":"ARV-471, a PROTAC\u00ae estrogen receptor (ER) degrader in advanced ER-positive\/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: Phase 2 expansion (VERITAC) of a phase 1\/2 study","volume":"83","author":"Schott","year":"2022","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101394","DOI":"10.1016\/j.esmoop.2023.101394","article-title":"205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+\/human epidermal growth factor receptor 2 (HER2)-advanced breast cancer","volume":"8","author":"Hurvitz","year":"2023","journal-title":"ESMO Open"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hamilton, E., Jeselsohn, R., Hurvitz, S., Juric, D., Han, H., Telli, M., Zahrah, G., Nanda, R., Zhang, Y., and Tan, W. (2024). Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER\u2013positive\/human epidermal growth factor receptor 2 (HER2)\u2013negative advanced breast cancer: Phase 1b cohort. Cancer Res., 84.","DOI":"10.1158\/1538-7445.SABCS23-PS15-03"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant in Advanced Breast Cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-023-01861-0","article-title":"Elacestrant: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40265-025-02266-x","article-title":"Imlunestrant: First Approval","volume":"86","author":"Keam","year":"2026","journal-title":"Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"for the EMBER-3 Study Group. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00277-017-3191-7","article-title":"Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: Is current clinical practice adequate?","volume":"97","author":"Leleu","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2009-05-221077","article-title":"Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia","volume":"115","author":"Pal","year":"2010","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"42331","DOI":"10.1038\/s41598-025-26351-z","article-title":"Safety evaluation of selective estrogen receptor degraders (SERDs) using real-world evidence from the FDA Adverse Event Reporting System (FAERS)","volume":"15","author":"Kang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102980","DOI":"10.1016\/j.ctrv.2025.102980","article-title":"Overcoming Resistance to CDK4\/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies","volume":"139","author":"Giugliano","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1097\/JS9.0000000000003208","article-title":"Dalpiciclib plus fulvestrant and pyrotinib in HR+\/HER2-low advanced breast cancer after progression on CDK4\/6 inhibition (DapPLE-HER): A Bayesian optimal phase II study","volume":"111","author":"Hao","year":"2025","journal-title":"Int. J. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103729","DOI":"10.1016\/j.breast.2024.103729","article-title":"Oral SERDs alone or in combination with CDK 4\/6 inhibitors in breast cancer: Current perspectives and clinical trials","volume":"75","author":"Apostolidou","year":"2024","journal-title":"Breast"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"117804","DOI":"10.1016\/j.taap.2026.117804","article-title":"Camizestrant-induced heart rate reduction is mediated via a sinoatrial node pacemaker channel mechanism","volume":"511","author":"Hall","year":"2026","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101454","DOI":"10.1016\/j.jacbts.2025.101454","article-title":"Selective Estrogen Receptor Degraders Induce Bradycardia by Modulating Nuclear Estrogen Signaling","volume":"11","author":"Basu","year":"2026","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA submission of vepdegestrant (ARV-471) to US FDA: The beginning of a new era of PROTAC degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_55","unstructured":"U.S. Food & Drug Administration (2026, May 12). FDA Approves Vepdegestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"PS18-09","DOI":"10.1158\/1538-7445.SABCS20-PS18-09","article-title":"Abstract PS18-09: Novel chimeric small molecule AC682 potently degrades estrogen receptor with oral anti-tumor efficacy superior to fulvestrant","volume":"81","author":"He","year":"2021","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41467-025-67485-y","article-title":"ER degradation for ER+\/HER2\u2013 advanced or metastatic breast cancer: A phase 1 trial","volume":"17","author":"Hamilton","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1158\/1538-7445.AM2024-4510","article-title":"Abstract 4510: Potent and orally efficacious PROTAC degraders of estrogen receptor \u03b1 (ER\u03b1)","volume":"84","author":"Rej","year":"2021","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"LB179","DOI":"10.1158\/1538-7445.AM2024-LB179","article-title":"Abstract LB179: Identification of the highly potent and orally available ER-targeting PROTAC degrader HP568 for the treatment of breast cancer","volume":"84","author":"Du","year":"2024","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acscentsci.6b00280","article-title":"Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras","volume":"2","author":"Lebraud","year":"2016","journal-title":"ACS Cent. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3892\/br.2026.2125","article-title":"Integrated transcriptomic and molecular docking analysis identifies Rhotekin 2 as a promising therapeutic target for overcoming gemcitabine resistance in cholangiocarcinoma","volume":"24","author":"Kidoikhammouan","year":"2026","journal-title":"Biomed. Rep."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/827\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:22:28Z","timestamp":1784002948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["pharmaceutics18070827"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18070827","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}